Mei, L, Xu, L, Wu, S, Wang, Y, Xu, C, Wang, L et al.. Discovery, structural optimization, and anti-tumor bioactivity evaluations of betulinic acid derivatives as a new type of RORγ antagonists. Eur J Med Chem. 2023;257 :115472. doi: 10.1016/j.ejmech.2023.115472. PubMed PMID:37236000 .
Caspersen, E, Guinot, PG, Rozec, B, Oilleau, JF, Fellahi, JL, Gaudard, P et al.. Comparison of landiolol and amiodarone for the treatment of new-onset atrial fibrillation after cardiac surgery (FAAC) trial: study protocol for a randomized controlled trial. Trials. 2023;24 (1):353. doi: 10.1186/s13063-023-07353-6. PubMed PMID:37226174 PubMed Central PMC10210392.
Kinch, MS, Kraft, Z, Schwartz, T. 2022 in review: FDA approvals of new medicines. Drug Discov Today. 2023;28 (8):103622. doi: 10.1016/j.drudis.2023.103622. PubMed PMID:37201782 .
Khera, HK, Venugopal, N, Karur, RT, Mishra, R, Kartha, RV, Rajasimha, HK et al.. Building cross-border collaborations to increase diversity and accelerate rare disease drug development - meeting report from the inaugural IndoUSrare Annual Conference 2021. Ther Adv Rare Dis. 2022;3 :26330040221133124. doi: 10.1177/26330040221133124. PubMed PMID:37180411 PubMed Central PMC10032468.
Michaeli, T, Jürges, H, Michaeli, DT. FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis. BMJ. 2023;381 :e073242. doi: 10.1136/bmj-2022-073242. PubMed PMID:37160306 PubMed Central PMC10167557.
Kranz, P, McGauran, N, Banzi, R, Ünal, C, Lotz, F, Kaiser, T et al.. Reforming EU and national orphan drug regulations to improve outcomes for patients with rare diseases. BMJ. 2023;381 :e072796. doi: 10.1136/bmj-2022-072796. PubMed PMID:37160303 .
Tu, SS, Nagar, S, Kesselheim, AS, Lu, Z, Rome, BN. Five-Year Sales for Newly Marketed Prescription Drugs With and Without Initial Orphan Drug Act Designation. JAMA. 2023;329 (18):1607-1608. doi: 10.1001/jama.2023.3079. PubMed PMID:37159041 PubMed Central PMC10170330.
Ogbole, OO, Akin-Ajani, OD, Ajala, TO, Ogunniyi, QA, Fettke, J, Odeku, OA et al.. Nutritional and pharmacological potentials of orphan legumes: Subfamily faboideae. Heliyon. 2023;9 (4):e15493. doi: 10.1016/j.heliyon.2023.e15493. PubMed PMID:37151618 PubMed Central PMC10161725.
Ciani, O, Meregaglia, M, Battaglia, MA, Brichetto, G, Conte, A, Gasperini, C et al.. Patient-reported outcome measures in drugs for neurological conditions approved by European Medicines Agency 2017-2022. Neurol Sci. 2023; :. doi: 10.1007/s10072-023-06825-6. PubMed PMID:37145229 .
Kim, H, Godman, B, Kwon, HY, Hong, SH. Introduction of managed entry agreements in Korea: Problem, policy, and politics. Front Pharmacol. 2023;14 :999220. doi: 10.3389/fphar.2023.999220. PubMed PMID:37124231 PubMed Central PMC10133550.
Busner, J, Pandina, G, Day, S, Mahableshwarkar, A, Kempf, L, Sheean, M et al.. Patient Centricity: Design and Conduct of Clinical Trials in Orphan Diseases: Third of Three Sets of Expanded Proceedings from the 2020 ISCTM Autumn Conference on Pediatric Drug Development. Innov Clin Neurosci. 2023;20 (1-3):25-31. . PubMed PMID:37122576 PubMed Central PMC10132279.
Okuyama, R. Strengthening the Competitiveness of Japan's Pharmaceutical Industry: Analysis of Country Differences in the Origin of New Drugs and Japan's Highly Productive Firm. Biol Pharm Bull. 2023;46 (5):718-724. doi: 10.1248/bpb.b23-00107. PubMed PMID:37121698 .
Hospodková, P, Gilíková, K, Barták, M, Marušáková, E, Tichopád, A. Opportunities and Threats of the Legally Facilitated Performance-Based Managed Entry Agreements in Slovakia: The Early-Adoption Perspective. Healthcare (Basel). 2023;11 (8):. doi: 10.3390/healthcare11081179. PubMed PMID:37108013 PubMed Central PMC10138524.
Kubota, Y, Narukawa, M. Randomized controlled trial data for successful new drug application for rare diseases in the United States. Orphanet J Rare Dis. 2023;18 (1):89. doi: 10.1186/s13023-023-02702-9. PubMed PMID:37076897 PubMed Central PMC10114466.
Bodó, I, Amine, I, Boban, A, Bumbea, H, Kulagin, A, Lukina, E et al.. Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations. Adv Ther. 2023;40 (6):2752-2772. doi: 10.1007/s12325-023-02510-4. PubMed PMID:37072660 PubMed Central PMC10112829.
Frost, J, Hall, A, Taylor, E, Lines, S, Mandizha, J, Pope, C et al.. How do patients and other members of the public engage with the orphan drug development? A narrative qualitative synthesis. Orphanet J Rare Dis. 2023;18 (1):84. doi: 10.1186/s13023-023-02682-w. PubMed PMID:37069597 PubMed Central PMC10108537.
Miller, KL, Miller Needleman, KI. The effect of the COVID-19 pandemic on US Food and Drug Administration-funded clinical trials and natural history studies for rare diseases. Contemp Clin Trials. 2023;129 :107198. doi: 10.1016/j.cct.2023.107198. PubMed PMID:37068589 PubMed Central PMC10105374.
Hems, S, Taylor, L, Jones, J, Holmes, E. Patient-based evidence: its role in decision making on end-of-life, orphan, and ultra-orphan medicines. Int J Technol Assess Health Care. 2023;39 (1):e19. doi: 10.1017/S026646232300003X. PubMed PMID:37039484 .
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.